These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28478943)

  • 1. Feasibility, safety, and tolerance of subcutaneous synthetic canine B-type natriuretic peptide (syncBNP) in healthy dogs and dogs with stage B1 mitral valve disease.
    Oyama MA; Solter PF; Thorn CL; Stern JA
    J Vet Cardiol; 2017 Jun; 19(3):211-217. PubMed ID: 28478943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.
    Yata M; Kooistra HS; Beijerink NJ
    J Vet Intern Med; 2019 Mar; 33(2):462-470. PubMed ID: 30703246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
    Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
    J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ; Block CL; Laughlin DS; Oyama MA
    J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG; Falk T; Teerlink T; Guðmundsdóttir HH; Sigurðardóttir S; Rasmussen CE; Olsen LH
    Vet J; 2011 Sep; 189(3):349-52. PubMed ID: 20822939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease.
    Moonarmart W; Boswood A; Luis Fuentes V; Brodbelt D; Souttar K; Elliott J
    J Small Anim Pract; 2010 Feb; 51(2):84-96. PubMed ID: 20070494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    J Vet Cardiol; 2012 Sep; 14(3):399-408. PubMed ID: 22858663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission.
    Serres F; Pouchelon JL; Poujol L; Lefebvre HP; Trumel C; Daste T; Sampedrano CC; Gouni V; Tissier R; Hawa G; Chetboul V
    J Vet Cardiol; 2009 Dec; 11(2):103-21. PubMed ID: 19850546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom.
    Mattin MJ; Brodbelt DC; Church DB; Boswood A
    J Vet Intern Med; 2019 Mar; 33(2):445-454. PubMed ID: 30565334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
    BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.
    Forfia PR; Lee M; Tunin RS; Mahmud M; Champion HC; Kass DA
    J Am Coll Cardiol; 2007 Mar; 49(10):1079-88. PubMed ID: 17349888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma atrial natriuretic peptide and N-terminal pro B-type natriuretic peptide concentrations in dogs with right-sided congestive heart failure.
    Kanno N; Hori Y; Hidaka Y; Chikazawa S; Kanai K; Hoshi F; Itoh N
    J Vet Med Sci; 2016 May; 78(4):535-42. PubMed ID: 26607133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
    Eriksson AS; Häggström J; Pedersen HD; Hansson K; Järvinen AK; Haukka J; Kvart C
    J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study.
    Hezzell MJ; Boswood A; López-Alvarez J; Lötter N; Elliott J
    J Vet Cardiol; 2017 Aug; 19(4):325-338. PubMed ID: 28734620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease.
    Hezzell MJ; Boswood A; Chang YM; Moonarmart W; Souttar K; Elliott J
    J Vet Intern Med; 2012; 26(2):302-11. PubMed ID: 22369312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
    Borgarelli M; Ferasin L; Lamb K; Bussadori C; Chiavegato D; D'Agnolo G; Migliorini F; Poggi M; Santilli RA; Guillot E; Garelli-Paar C; Toschi Corneliani R; Farina F; Zani A; Dirven M; Smets P; Guglielmini C; Oliveira P; Di Marcello M; Porciello F; Crosara S; Ciaramella P; Piantedosi D; Smith S; Vannini S; Dall'Aglio E; Savarino P; Quintavalla C; Patteson M; Silva J; Locatelli C; Baron Toaldo M
    J Vet Cardiol; 2020 Feb; 27():34-53. PubMed ID: 32032923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of treatment on respiratory rate, serum natriuretic peptide concentration, and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure secondary to degenerative mitral valve disease and dilated cardiomyopathy.
    Schober KE; Hart TM; Stern JA; Li X; Samii VF; Zekas LJ; Scansen BA; Bonagura JD
    J Am Vet Med Assoc; 2011 Aug; 239(4):468-79. PubMed ID: 21838584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure.
    Chen HH; Redfield MM; Nordstrom LJ; Horton DP; Burnett JC
    J Card Fail; 2004 Apr; 10(2):115-9. PubMed ID: 15101022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.